RxDoctor Payments Data

Hazem Eissa, MD

Pain Medicine · New Orleans, LANPI 1649238734

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,920 of the $50,429 with a category attached, or 75.2%. AbbVie accounts for 85.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $14,677 and has fallen 86.4% since, to $1,989 in 2025. Among pain medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,429in general payments, 2019–2025

Across 252 payments — averaging $200.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43K
  • Abbott$2K
  • Boston Scientific$2K
  • Nevro Corp.$720
  • Medtronic$692
  • Biotronik NRO, Inc.$271
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$37,92075%
  • Travel & lodging$3,4557%
  • Food & beverage$9,05418%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,429 in reported general payments places this provider in the 95th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$61,400
Medicare patients
198
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen427$12,329
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen323$6,980
Morphine Sulfate ErMorphine Sulfate114$3,738
Buprenorphine17$3,519
Pregabalin230$3,424
Oxycodone Hcl167$2,896
Gabapentin80$1,623
Tramadol Hcl174$1,168
Tizanidine Hcl74$948
Baclofen47$514
Hydromorphone Hcl29$343
Methocarbamol30$305
Morphine Sulfate13$242
Duloxetine Hcl15$148
Cyclobenzaprine Hcl15$86

Paid to pharmacies, not to this prescriber.

Other pain medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →